Skip to main content

Advertisement

SpringerLink
Log in

Chemotherapeutic advances in pancreatic cancer

  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Advances in chemotherapy for pancreatic cancer have been limited. In the past decade, the standard therapy for metastatic disease has switched from 5-fluorouracil (5-FU) to gemcitabine. However, several other cytotoxic agents have shown limited but promising efficacy in pancreatic cancer, and many of these appear to be well suited for combination chemotherapy. Although 5-FU and cisplatin have not demonstrated substantial survival benefits when combined with gemcitabine, results of several phase III trials with other agents are still pending. For locally advanced disease, most recent studies have incorporated gemcitabine into combined-modality therapy. Similarly, in surgically resectable disease, current trials are incorporating gemcitabine into adjuvant therapy. Other trials are using neoadjuvant therapy as a possible means to improve upon current surgical results. However, much hope comes from the development of newer “targeted” therapies for this disease. Although matrix metalloproteinase inhibitors and farnesyl transferase inhibitors did not appear to be effective in initial studies, other targeted therapies are beginning to enter clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Burris HA, III, Moore MJ, Andersen J, et al.: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997, 15:2403–2413. Randomized trial that established gemcitabine activity in pancreatic cancer and was the first to test a new parameter for the clinical effect and clinical benefit response.

    PubMed  CAS  Google Scholar 

  2. Tempero M, Plunkett W, Ruiz van Haperen V, et al.: Randomized phase II trial of dose intense gemcitabine by standard infusion vs. fixed dose rate in metastatic pancreatic adenocarcinoma [abstract]. Proc ASCO 1999, 18:273a.

    Google Scholar 

  3. Maisey, N, Chau I, Cunningham D, et al.: Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU)with PVI 5-FU plus mitomycin in inoperable pancreatic cancer. J Clin Oncol 2002, 20:3130–3136.

    Article  PubMed  CAS  Google Scholar 

  4. Ducreux M, Rougier P, Pignon J-P, et al.: A randomized trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma. Ann Oncol 2002, 13:1185–1191.

    Article  PubMed  CAS  Google Scholar 

  5. Cartwright TH, Cohn A, Varkey JA, et al.: Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. J Clin Oncol 2002, 20:160–164.

    Article  PubMed  CAS  Google Scholar 

  6. Okada S, Okusaka T, Ueno H, et al.: A phase II and pharmacokinetic trial of S-1 in paitents with advanced pancreatic cancer (APC) [abstract]. Proc ASCO 2002, 21:682a.

    Google Scholar 

  7. Miller KD, Picus J, Blanke C, et al.: Phase II study of the multitargeted antifolate LY 231514 (Alimta, MTA, pemetrexed disodium) in patients with advanced pancreatic cancer. Ann Oncol 2000, 11:101–103.

    Article  PubMed  CAS  Google Scholar 

  8. Smith DB, Gallagher N, Garnett S: A phase II/III trial of efficacy and tolerability of ZD9331 vs gemcitabine in pancreatic cancer [abstract]. Proc ASCO 2002, 21:144a.

    Google Scholar 

  9. Yip D, Halford S, Karapetis C, et al.: A phase II trial of Caelyx (liposomal doxorubicin, Doxil) in the treatment of advanced pancreatic carcinoma [abstract]. Proc ASCO 1999, 18:306a.

    Google Scholar 

  10. Wils J, Bleiberg H, Blijham G, et al.: Phase II study of epirubicin in advanced adenocarcinoma of the pancreas. Eur J Cancer Clin Oncol 1985, 21:191–194.

    Article  PubMed  CAS  Google Scholar 

  11. Topham C, Glees J, Coombes RC: Comparison of single-agent epirubicin and 5-fluorouracil/epirubicin/mitomycin in patients with advanced adenocarcinoma of the pancreas. Oncology 1993, 50(Suppl 1):78–83.

    Article  PubMed  Google Scholar 

  12. Kornek G, Raderer M, Schenk T, et al.: Phase I/II trial of dexverapamil, epirubicin, and granulocyte-macrophage-colony stimulating factor in patients with advanced pancreatic adenocarcinoma. Cancer 1995, 76:1356–1362.

    Article  PubMed  CAS  Google Scholar 

  13. Wils JA, Kok T, Wagener DJ, et al.: Activity of cisplatin in adenocarcinoma of the pancreas. Eur J Cancer 1993, 9A:203–204.

    Article  Google Scholar 

  14. Rougier P, Ducreux M, Ould Kaci M, et al.: Randomized phase II study of oxaliplatin alone (OXA), 5-fluorouracil (5FU) alone, and the two drugs combined (OXA-FU) in advanced or metastatic pancreatic adenocarcinoma (APC) [abstract]. Proc ASCO 2000, 19:262a.

    Google Scholar 

  15. Stevenson JP, Scher RM, Kosierowski R, et al.: Phase II trial of topotecan as a 21-day continuous infusion in patients with advanced or metastatic adenocarcinoma of the pancreas. Eur J Cancer 1998, 34:1358–1362.

    Article  PubMed  CAS  Google Scholar 

  16. Stehlin JS, Giovanella BC, Natelson EA, et al.: A study of 9-nitrocamptothecin (RFS-2000) in patients with advanced pancreatic cancer. Int J Oncol 1999, 14:821–831.

    PubMed  CAS  Google Scholar 

  17. Rivkin S, Burris H, III, Gerstein H, et al.: A phase II study of rubitecan (RFS 2000, 9NC, 9-nitro-20(S)-camptothecin) in patients with refractory pancreatic cancer [abstract]. Proc ASCO 2000, 19:262a.

    Google Scholar 

  18. D’Adamo D, Hammond L, Donehower R, et al.: Final results of a phase II study of DX-8951f (exatecan mesylate, DX) in advanced pancreatic cancer [abstract]. Proc ASCO 2001, 20:134a.

    Google Scholar 

  19. Wagener DJT, Verdonk HER, Dirix LY, et al.: Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study. Ann Oncol 1995, 6:129–132.

    PubMed  CAS  Google Scholar 

  20. Whitehead RP, Jacobson J, Brown TD,et al.: Phase II trial of paclitaxel and granulocyte colony-stimulating factor in patients with pancreatic carcinoma: a Southwest Oncology Group study. J Clin Oncol 1997, 15:24142419.

    Google Scholar 

  21. De ForniM, Rougier Ph, Adenis A, et al.: Phase II study of Taxotere (RP 56976, docetaxel) in locally advanced and/or metastatic pancreatic cancer [abstract]. Ann Oncol1994, 5(Suppl 5):202.

    Google Scholar 

  22. Okada S, Sakata Y, Matsuno S, et al.: Phase II study of docetaxel in patients with metastatic pancreatic cancer: a Japanese cooperative study. Br J Cancer 1999, 80:438–443.

    Article  PubMed  CAS  Google Scholar 

  23. Berlin JD, Adak S, Vaughn DJ, et al.: A phase II study of gemcitabine and 5-fluorouracil in metastatic pancreatic cancer: an Eastern Cooperative Oncology Group study (E3296). Oncology 2000, 58:215–218.

    Article  PubMed  CAS  Google Scholar 

  24. Hidalgo M, Castellano D, Paz-Ares L, et al.: Phase I–II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer. J Clin Oncol 1999, 17:585–592.

    PubMed  CAS  Google Scholar 

  25. Marantz A, Almira E, et al.: Phase II trial of gemcitabine (GEM), 5-fluorouracil (5-FU) and leucovorin (LV) in advanced pancreatic cancer [abstract]. Eur J Cancer 1999, 35:S157.

    Google Scholar 

  26. Berlin JD, Catalano P, Thomas JP, et al.: Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group trial E2297. J Clin Oncol 2002, 20:3270–3275. This large randomized trial compares gemcitabine with gemcitabine plus 5-FU. The authors confirm single-agent survival for gemcitabine from the Burris trial [1] and do not use the “loading” first cycle featured in the Burris trial.

    Article  PubMed  CAS  Google Scholar 

  27. Kindler HL, Dugan W, Hochster H, et al.: Clinical outcome in patients (pts) with advanced pancreatic cancer treated with pemetrexed/gemcitabine [abstract]. Proc ASCO 2002, 21:125a.

    Google Scholar 

  28. Heinemann V, Wilke H, Mergenthaler HG, et al.: Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer. Ann Oncol 2000, 11:1399–1403.

    Article  PubMed  CAS  Google Scholar 

  29. Philip PA, Zalupski M, Vaitvkevicius VK, et al.: Phase II study of gemcitabine and cisplatin in advanced or metastatic pancreatic cancer. Cancer 2001, 92:569–577.

    Article  PubMed  CAS  Google Scholar 

  30. Colucci G, Giuliani F, Gebbia V, et al.: Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologico dell’Italia Meidionale. Cancer 2002, 94:902–910. Confirms response rate for gemcitabine plus cisplatin, toxicity of the regimen, and survival data.

    Article  PubMed  CAS  Google Scholar 

  31. Wang X-Y, Ni Q-X, Jin M-L, et al.: Gemcitabine versus gemcitabine plus cisplatin as first-line treatment in Chinese patients with locally advanced pancreatic cancer: a multicenter randomized study [abstract]. Proc ASCO 2002, 21:616a.

    Google Scholar 

  32. Louvet C, Andre T, Lledo G, et al.: Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study. J Clin Oncol 2002, 20:1512–1518.

    Article  PubMed  CAS  Google Scholar 

  33. Alberts SR, Townley P, Cha SS, et al.: Oxaliplatin and gemcitabine for patients with pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) phase II study [abstract]. Proc ASCO 2002, 21:126a.

    Google Scholar 

  34. Rocha Lima CMS, Savarese D, Bruckner H, et al.: Irinotecan plus gemcitabine induces both radiographic and CA 19–9 tumor marker responses in patients with previously untreated advanced pancreatic cancer. J Clin Oncol 2002, 20:1182–1191.

    Article  PubMed  Google Scholar 

  35. Shepard RC, Levy D, Stuart K, et al.: Pancreatic cancer: biweekly gemcitabine/docetaxel chemotherapy [abstract]. Proc ASCO 2001, 20:154a.

    Google Scholar 

  36. Stathopoulos GP, Mavroudis D, Tsavaris N, et al.: Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: a phase II study of the Greek Cooperative Group for Pancreatic Cancer. Ann Oncol 2001, 12:101–103.

    Article  PubMed  CAS  Google Scholar 

  37. Ryan DP, Kulke MH, Fuchs CS, et al.: A phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic cancer. Cancer 2002, 94:97–103.

    Article  PubMed  CAS  Google Scholar 

  38. Lutz, MP, Ducreux M, Wagener T, et al.: Docetaxel/gemcitabine or docetaxel/cisplatin in advanced pancreatic carcinoma: a randomized phase II study of the EORTC-GI group [abstract]. Proc ASCO 2002, 21:498a.

    Google Scholar 

  39. Hoffman JP, McGinn CJ, Szarka C, et al.: A phase I study of preoperative gemcitabine with radiation therapy followed by postoperative gemcitabine for patients with localized, resectable pancreatic adenocarcinoma [abstract]. Proc ASCO 1998, 17:283a.

    Google Scholar 

  40. Epelbaum R, Rosenblatt E, Nasrallah S, et al.: A phase II study of gemcitabine (GEM) combined with radiation therapy (RT) in patients with localized, unresectable pancreatic cancer [abstract]. Proc ASCO 2000, 19:265a.

    Google Scholar 

  41. Blackstock AW, Bernard SA, Richards F, et al.: Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer. J Clin Oncol 1999, 17:2208–2212. This study used preclinical data to optimize gemcitabine as a radiation sensitizer.

    PubMed  CAS  Google Scholar 

  42. McGinn CJ, Zalupski MM, Shureiqi I, et al.: Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2001, 19:4202–4208. This study used the unique concept of testing radiotherapy as an adjunct to chemotherapy and dose-escalated the radiation in combination with full-dose gemcitabine chemotherapy.

    PubMed  CAS  Google Scholar 

  43. Talamonti MS, Catalano PJ, Vaughn DJ, et al.: Eastern Cooperative Oncology Group phase I trial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer: a regimen with unexpected early toxicity. J Clin Oncol 2000, 18:3384–3389.

    PubMed  CAS  Google Scholar 

  44. Aitken CL, Safar AM, Recht A, Stuart KE: Phase I trial of gemcitabine, cisplatin (CDDP) and external beam radiation therapy (EBRT) for pancreatic cancer [abstract]. Proc ASCO 2002, 21:2221a.

    Google Scholar 

  45. Safran H, Moore T, Iannitti D, Dipitrello T, et al.: Paclitaxel and concurrent radiation for locally advanced pancreatic cancer. Int J Rad Oncol Biol Phys 2001, 49:1275–1279.

    Article  CAS  Google Scholar 

  46. Kemp KR, Liehr JG, Giovanella B: Combined radiation and 0-nitrocamptothecin (Rubitecan) in the treatment of locally advanced pancreatic cancer. Ann N Y Acad Sci 2000, 922:320–323.

    Article  PubMed  CAS  Google Scholar 

  47. Kalser MH, Ellenberg SS: Pancreatic cancer: adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985, 120:899–903.

    PubMed  CAS  Google Scholar 

  48. Klinkenbijl JH, Jeekel J, Sahmoud T, et al.: Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC Gastrointestinal Tract Cancer Cooperative Group. Ann Surg 1999, 230:776–784. Although design flaws prevented this trial from confirming or refuting the prior GITSG trial, it is notable as a large randomized study with data on periampullary tumors as well.

    Article  PubMed  CAS  Google Scholar 

  49. Neoptolemos JP, Dunn JA, Stocken DD, et al.: Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomized controlled trial. Lancet 2001, 358:1576–1585. Another flawed trial of adjuvant therapy, but it suggests the possibility of investigating chemotherapy alone as adjuvant therapy and has led to a large randomized trial of surgery alone compared with surgery plus 5-FU and surgery plus gemcitabine.

    Article  PubMed  CAS  Google Scholar 

  50. Allen AM, Zalupski MM, Eckhauser F, et al.: A phase I trial of radiation (RT) dose escalation with concurrent full dose gemcitabine (GEM) following resection of pancreatic cancer [abstract]. Proc ASCO 2002, 21:549a.

    Google Scholar 

  51. Hoffman JP, Lipsitz S, Pisansky T, et al.: Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: an Eastern Cooperative Oncology Group study. J Clin Oncol 1998, 16:317–323.

    PubMed  CAS  Google Scholar 

  52. Pisters PWT, Abbruzzesse JL, Janjan NA, et al.: Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma. J Clin Oncol 1998, 16:3843–3850.

    PubMed  CAS  Google Scholar 

  53. Wolff RA, Evans DB, Crane CH, et al.: Initial results of preoperative gemcitabine (GEM)-based chemotadiation for resectable pancreatic adenocarcinoma [abstract]. Proc ASCO 2002, 21:516.

    Google Scholar 

  54. Bramhall SR, Rosemurgy A, Brown PD, et al.: Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol 2001, 19:3447–3455. Although it had negative results, this randomized trial confirms gemcitabine activity. In addition, the single-agent activity for the highest dose level of marimastat suggests a dose-response relationship for this unique class of agents.

    PubMed  CAS  Google Scholar 

  55. Bramhall SR, Schulz J, Nemunaitis J, et al.: A double-blind placebo-controlled, randomized study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in paitents with advanced pancreatic cancer. Br J Cancer 2002, 87:161–167.

    Article  PubMed  CAS  Google Scholar 

  56. Cohen SJ, Ho L, Ranganathan S, et al.: Phase II and pharmacodynamic trial of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma [abstract]. Proc ASCO 2002, 21:137a.

    Google Scholar 

  57. Macdonald JS, Chansky K, Whitehead R, et al.: A phase II study of farnesyl trasferase inhibitor R115777 in pancreatic cancer. A Southwest Oncology Group (SWOG) study [abstract]. Proc ASCO 2002, 21:138a.

    Google Scholar 

  58. Van CutsemE, Karasek P, Oettle H, et al.: Phase III trial comparing gemcitabine + R115777 (Zarnestra) versus gemcitabine + placebo in advanced pancreatic cancer (PC) [abstract]. Proc ASCO 2002, 21:130a.

    Google Scholar 

  59. Abbruzzesse JL, Rosenberg A, Xiong Q, et al.: Phase II study of anti-epidermal growth factor receptor (EGFR) antibody cetuximab (IMC-C225) in combination with gemcitabine in patients with advanced pancreatic cancer [abstract]. Proc ASCO 2001, 20:130a.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Oncology, Vanderbilt Ingram Cancer Center, Vanderbilt University, 777 Preston Research Building, 37232-6307, Nashville, TN, USA

    Jordan D. Berlin MD

Authors
  1. Jordan D. Berlin MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mace L. Rothenberg MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Berlin, J.D., Rothenberg, M.L. Chemotherapeutic advances in pancreatic cancer. Curr Oncol Rep 5, 219–226 (2003). https://doi.org/10.1007/s11912-003-0113-8

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-003-0113-8

Keywords

Search

Navigation